Table 5 In vitro cytotoxic screening of 5a–n against A549 human lung cancer cells
Comp. | Validity (%) for sample concentrations (µg/mL) | IC50 (µg/mL) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
0 | 1 | 10 | 31.25 | 62.50 | 125 | 250 | 500 | 1000 | ||
5a | 100 | 95.6 | 91.4 | 86.8 | 82.3 | 79.7 | 75.4 | 45.5 | 12.5 | 413 |
5b | 100 | 91.2 | 85.4 | 83.99 | 67.8 | 64.3 | 57.1 | 44.2 | 17.8 | 402 |
5c | 100 | 91.2 | 90.1 | 89.2 | 80.9 | 62.6 | 59.8 | 46.3 | 14.9 | 415 |
5d | 100 | 98.4 | 91.7 | 88.9 | 82.2 | 78.8 | 73.01 | 58.6 | 18.1 | 574 |
5e | 100 | 93.4 | 90.2 | 85.6 | 77.3 | 72.2 | 65.7 | 62.2 | 48.9 | 847 |
5f | 100 | 94.97 | 89.8 | 86.96 | 83.8 | 79.2 | 75.4 | 65.5 | 12.6 | 567 |
5g | 100 | 93.7 | 90.3 | 88.7 | 78.6 | 84.1 | 75.7 | 56.3 | 16.8 | 572 |
5h | 100 | 92.9 | 91.4 | 90.3 | 88.7 | 85.7 | 82.7 | 77.2 | 68.0 | 1607 |
5i | 100 | 93.3 | 92.2 | 91.4 | 85.6 | 81.3 | 76.9 | 63.2 | 49.3 | 896 |
5j | 100 | 92.9 | 84.6 | 83.6 | 82.5 | 81.6 | 77.5 | 71.4 | 52.5 | 1046 |
5k | 100 | 95.2 | 92.3 | 85.9 | 83.9 | 79.6 | 76.9 | 60.9 | 22.6 | 613 |
5l | 100 | 96.5 | 93.6 | 75.4 | 72.2 | 68.01 | 62.9 | 51.9 | 41.3 | 577 |
5m | 100 | 94.01 | 92.5 | 70.7 | 67.5 | 64.5 | 56.5 | 37.3 | 20.1 | 357 |
5n | 100 | 94.2 | 91.2 | 83.1 | 78.6 | 70.7 | 58.9 | 27.3 | 8.02 | 380 |